Clinical Trial Update: Zevalin Plus BuCyE High-dose Therapy in B-cell Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial update evaluating Zevalin in combination with BuCyE high-dose therapy for B-cell non-Hodgkin lymphoma; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• BUSULFAN (Busulfan)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Etoposide (Etoposide)
• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: Asan Medical Center | Conditions: Non-Hodgkin's Lymphoma | Phase 2 | Status: COMPLETED